

April 16, 2021

Protamine Sulfate Supply Update

Dear Valued Customer,

We have identified an isolated issue related to the manufacture of **Protamine Sulfate Injection, USP Single Dose Vials** that has temporarily affected our ability to manufacture Protamine. We have addressed the issue, which will restore our ability to provide consistent supply.

Although we provided a significant quantity of Protamine in March, we understand it may not have satisfied each customer's needs.

We have set aside a limited supply of previously manufactured product for medically necessary direct orders. We anticipate readily available quantities of both presentations in May and will expedite shipping into the wholesalers as supply is restored.

We understand the significance of Protamine to patient care and are working diligently to restore product availability.

For product availability updates, please visit our web site [at www.fresenius-kabi.com/us/pharmaceutical-product-availability](http://www.fresenius-kabi.com/us/pharmaceutical-product-availability) or call our Customer Service team at 1-888-386-1300, Monday–Friday between 7 a.m. and 6 p.m. (CST).

For clinical questions, please contact Fresenius Kabi USA Medical Affairs at 1-800-551-7176, Monday–Friday between 8 a.m. and 5 p.m. (CST) or email medinfo.USA@fresenius-kabi.com.

Protamine Sulfate Injection, USP

| Unit of Sale NDC | Product Description | Concentration | Fill Volume | Pack Size |
|------------------|----------------------|---------------|-------------|-----------|
| 63323-229-05 | 50 mg per 5 mL SDV | 10 mg per mL | 5 mL | 25 |
| 63323-229-30 | 250 mg per 25 mL SDV | 10 mg per mL | 25 mL | 1 |

Sincerely,



Matt Kozak
Senior Manager, Marketing

###